Task: Answer Verification
Input (English): Question: Does alirocumab , a Therapeutic Human Antibody to PCSK9 , Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes?
Answer: These results suggest that inhibition of PCSK9 with alirocumab has no effect on CD81 and does not result in increased susceptibility to HCV entry.
Output (English): no